A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay

Michele M. Gage, Martin Rosman, W. Charles Mylander, Erica Giblin, Hyun Seok Kim, Leslie Cope, Christopher B Umbricht, Antonio C Wolff, Lorraine Tafra

Research output: Contribution to journalArticle

Abstract

Background Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer can be challenging, and Oncotype DX (ODX) is often used to gain insight. However, it is still unclear whether ODX can benefit in all cases. To clarify ODX's usefulness we sought to develop a model using readily available pathologic markers to help clinicians make that determination. Patients and Methods Clinical pathologic data from 221 hormone receptor-positive, HER2-negative invasive breast cancer patients was used to create a model. The model was then validated on a second institution's set of 319 patients. Results The model has 2 simple rules: low grade and positive progesterone receptor tumors (LG+PR) are low risk, and high grade or low estrogen receptor (ER) (ER <20%) tumors (HG/LER) are high risk. The TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial thresholds of Recurrence Score (RS) ≤ 10, when chemotherapy is of little benefit, and RS ≥ 26 when chemotherapy might be beneficial were used to judge model performance. Impressively, the misclassifications of an HG/LER patient who has an RS ≤ 10 were 0% and 2%, and for LG+PR patients who had an RS ≥ 26 were 0% and 2.6%. In the validation set, 28% (66 of 232) of the indeterminate group (neither in the HG/LER nor the LG+PR groups) had an RS ≤ 10 or an RS ≥ 26; this group might clinically benefit from ODX. Conclusion A simple 2-rule model based on readily available pathologic data was developed and validated, which categorized patients into high and low risk for recurrence. Identification of patients who are unlikely to benefit from ODX testing could result in significant cost avoidance.

Original languageEnglish (US)
Pages (from-to)467-472
Number of pages6
JournalClinical Breast Cancer
Volume15
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Recurrence
Genes
Drug Therapy
Estrogen Receptors
Breast Neoplasms
Progesterone Receptors
Neoplasms
Hormones
Costs and Cost Analysis
Therapeutics

Keywords

  • Classification model
  • Grade
  • Oncotype DX
  • Predictive value of tests
  • Risk assessment
  • TAILORx
  • Tumor markers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. / Gage, Michele M.; Rosman, Martin; Mylander, W. Charles; Giblin, Erica; Kim, Hyun Seok; Cope, Leslie; Umbricht, Christopher B; Wolff, Antonio C; Tafra, Lorraine.

In: Clinical Breast Cancer, Vol. 15, No. 6, 01.12.2015, p. 467-472.

Research output: Contribution to journalArticle

Gage, Michele M. ; Rosman, Martin ; Mylander, W. Charles ; Giblin, Erica ; Kim, Hyun Seok ; Cope, Leslie ; Umbricht, Christopher B ; Wolff, Antonio C ; Tafra, Lorraine. / A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. In: Clinical Breast Cancer. 2015 ; Vol. 15, No. 6. pp. 467-472.
@article{f3f1d9fb147b44d6baf8fc8700bfef23,
title = "A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay",
abstract = "Background Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer can be challenging, and Oncotype DX (ODX) is often used to gain insight. However, it is still unclear whether ODX can benefit in all cases. To clarify ODX's usefulness we sought to develop a model using readily available pathologic markers to help clinicians make that determination. Patients and Methods Clinical pathologic data from 221 hormone receptor-positive, HER2-negative invasive breast cancer patients was used to create a model. The model was then validated on a second institution's set of 319 patients. Results The model has 2 simple rules: low grade and positive progesterone receptor tumors (LG+PR) are low risk, and high grade or low estrogen receptor (ER) (ER <20{\%}) tumors (HG/LER) are high risk. The TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial thresholds of Recurrence Score (RS) ≤ 10, when chemotherapy is of little benefit, and RS ≥ 26 when chemotherapy might be beneficial were used to judge model performance. Impressively, the misclassifications of an HG/LER patient who has an RS ≤ 10 were 0{\%} and 2{\%}, and for LG+PR patients who had an RS ≥ 26 were 0{\%} and 2.6{\%}. In the validation set, 28{\%} (66 of 232) of the indeterminate group (neither in the HG/LER nor the LG+PR groups) had an RS ≤ 10 or an RS ≥ 26; this group might clinically benefit from ODX. Conclusion A simple 2-rule model based on readily available pathologic data was developed and validated, which categorized patients into high and low risk for recurrence. Identification of patients who are unlikely to benefit from ODX testing could result in significant cost avoidance.",
keywords = "Classification model, Grade, Oncotype DX, Predictive value of tests, Risk assessment, TAILORx, Tumor markers",
author = "Gage, {Michele M.} and Martin Rosman and Mylander, {W. Charles} and Erica Giblin and Kim, {Hyun Seok} and Leslie Cope and Umbricht, {Christopher B} and Wolff, {Antonio C} and Lorraine Tafra",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.clbc.2015.04.006",
language = "English (US)",
volume = "15",
pages = "467--472",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay

AU - Gage, Michele M.

AU - Rosman, Martin

AU - Mylander, W. Charles

AU - Giblin, Erica

AU - Kim, Hyun Seok

AU - Cope, Leslie

AU - Umbricht, Christopher B

AU - Wolff, Antonio C

AU - Tafra, Lorraine

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer can be challenging, and Oncotype DX (ODX) is often used to gain insight. However, it is still unclear whether ODX can benefit in all cases. To clarify ODX's usefulness we sought to develop a model using readily available pathologic markers to help clinicians make that determination. Patients and Methods Clinical pathologic data from 221 hormone receptor-positive, HER2-negative invasive breast cancer patients was used to create a model. The model was then validated on a second institution's set of 319 patients. Results The model has 2 simple rules: low grade and positive progesterone receptor tumors (LG+PR) are low risk, and high grade or low estrogen receptor (ER) (ER <20%) tumors (HG/LER) are high risk. The TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial thresholds of Recurrence Score (RS) ≤ 10, when chemotherapy is of little benefit, and RS ≥ 26 when chemotherapy might be beneficial were used to judge model performance. Impressively, the misclassifications of an HG/LER patient who has an RS ≤ 10 were 0% and 2%, and for LG+PR patients who had an RS ≥ 26 were 0% and 2.6%. In the validation set, 28% (66 of 232) of the indeterminate group (neither in the HG/LER nor the LG+PR groups) had an RS ≤ 10 or an RS ≥ 26; this group might clinically benefit from ODX. Conclusion A simple 2-rule model based on readily available pathologic data was developed and validated, which categorized patients into high and low risk for recurrence. Identification of patients who are unlikely to benefit from ODX testing could result in significant cost avoidance.

AB - Background Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer can be challenging, and Oncotype DX (ODX) is often used to gain insight. However, it is still unclear whether ODX can benefit in all cases. To clarify ODX's usefulness we sought to develop a model using readily available pathologic markers to help clinicians make that determination. Patients and Methods Clinical pathologic data from 221 hormone receptor-positive, HER2-negative invasive breast cancer patients was used to create a model. The model was then validated on a second institution's set of 319 patients. Results The model has 2 simple rules: low grade and positive progesterone receptor tumors (LG+PR) are low risk, and high grade or low estrogen receptor (ER) (ER <20%) tumors (HG/LER) are high risk. The TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial thresholds of Recurrence Score (RS) ≤ 10, when chemotherapy is of little benefit, and RS ≥ 26 when chemotherapy might be beneficial were used to judge model performance. Impressively, the misclassifications of an HG/LER patient who has an RS ≤ 10 were 0% and 2%, and for LG+PR patients who had an RS ≥ 26 were 0% and 2.6%. In the validation set, 28% (66 of 232) of the indeterminate group (neither in the HG/LER nor the LG+PR groups) had an RS ≤ 10 or an RS ≥ 26; this group might clinically benefit from ODX. Conclusion A simple 2-rule model based on readily available pathologic data was developed and validated, which categorized patients into high and low risk for recurrence. Identification of patients who are unlikely to benefit from ODX testing could result in significant cost avoidance.

KW - Classification model

KW - Grade

KW - Oncotype DX

KW - Predictive value of tests

KW - Risk assessment

KW - TAILORx

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=84947043464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947043464&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2015.04.006

DO - 10.1016/j.clbc.2015.04.006

M3 - Article

C2 - 26072275

AN - SCOPUS:84947043464

VL - 15

SP - 467

EP - 472

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -